Tags » GlaxoSmithKline

Health:Pollen Got Cha? Its The Season--And Bless You....

The experts say we may experience a “Pollen Vortex” this spring—with allergy and asthma sufferers in for a pretty heavy bout of symptoms. And Weight loss surgery that can change your sense of taste and appetite, and powdered alcohol??Really??? 34 more words


The pharma industry's blockbuster $29 billion, three-way deal is all about specialization

Novartis, GlaxoSmithKline, and Eli Lilly just announced a complicated four-part deal worth about $28.5 billion. When the dust settles, the three companies will look very different from before and, crucially, from each other. 555 more words

Novartis, GSK, Lilly sign multibillion-dollar deals

GENEVA – Drugmaker Novartis says it has signed several multibillion-dollar deals with GlaxoSmithKline and Lilly that will affect some 15,000 of its employees.

The Basel, Switzerland-based company said Tuesday it will buy GSK’s oncology products business for $14.5 billion, plus up to $1.5 billion more if certain milestones are met. 78 more words


What I believe

I believe Seroxat is defective and dangerous.

I believe that Glaxo has hidden clinical trial data that shows exactly how dangerous a drug it is. 102 more words

Big Pharma

Investigational drug for psoriasis by Galapagos and GlaxoSmithKline

A phase 2a multi-center, randomized, double-blind, placebo-controlled, dose ranging study evaluated the efficacy of GSK2586184 in 66 patients with chronic plaque psoriasis. Compared to placebo, a significantly higher proportion of patients treated with the investigational drug met the primary endpoint of achieving 75% improvement from baseline in Psoriasis Area Severity Index score at week 12. 63 more words

Drugs / Natural Products / Devices

FDA Breakthrough Therapy Designation: Fifth Drug Receives FDA Approval

The FDA approves on April 17th, GlaxoSmithKline’s orphan drug Arzerra (Ofatumumab injection for intravenous infusion), the 5th drug to have the coveted Breakthrough Therapy Designation (BTD). 315 more words

FDA Breakthrough Therapy Designation

US FDA approves GSK's once-weekly type 2 diabetes drug, Tanzeum

The US Food and Drug Administration (FDA) has approved GlaxoSmithKline’s Tanzeum (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment for type 2 diabetes. 260 more words

Aurous Posts